Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

NCT04725188 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

255

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Non Small Cell Lung Cancer

Interventions

BIOLOGICAL: Pembrolizumab/Vibostolimab coformulation
DRUG: Docetaxel
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC